Piramal Pharma Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives

3
Nandini Piramal, Peter DeYoung, Vivek Valsaraj

Analysts

12
Abdulkader Puranwala, Alankar Garude, Amey Chalke, Bharat Sheth, Devang Shah, Karan Gupta, Parikshit Gupta, Raj, Sajal Kapoor, Shyam Srinivasan, Tushar Manudhane, Vinod Jain

Financials & KPIs

Note: Transcript states CapEx guidance in INR terms as "INR 120 million–135 million"; this may be a transcription error for USD.

Geographic & Segment Commentary

• CDMO: 19% YoY revenue growth, broad-based across Indian and overseas assets. Strong execution, improved U.S. biopharma funding, and higher RFP activity—especially toward overseas sites with favorable margin profiles. ADC capacity expansion (Riverview payload-linker, Lexington sterile injectables) strengthens integrated offering.
• Complex Hospital Generics (CHG): Revenue grew 17% YoY to ₹743 crore. U.S. leadership maintained in Sevoflurane (48% share) and Intrathecal Baclofen; encouraging traction in ex-U.S. inhalation anesthesia markets. Kenalog supplies expected from Q2 FY2027.
• Consumer Healthcare (CHC): Mid-teen revenue growth with power brands growing 23% and e-commerce 40%. Brand contribution at 53% of sales; ~12% of sales allocated to media/trade promotion. Launched new master brand "i-choose" for women's intimate care; premiumization and cost discipline supporting margins.
• India vs. Overseas: CDMO split roughly 48% overseas / 52% India; overseas gross margins higher (75–85%) but lower utilization. Overseas scale-up is the primary lever for overall margin expansion.

Company-Specific & Strategic Commentary

• ADC Expansion: Inaugurated commercial-scale payload-linker facility at Riverview; Lexington sterile injectable expansion on track for end-2027 (calendar year). Part of $90 million U.S. expansion program strengthening integrated ADC capabilities.
• Ajinomoto Collaboration: Strategic partnership combining AJICAP site-specific conjugation technology with Piramal's ADC manufacturing expertise—signals compatibility and streamlines tech transfer/scale-up.
• Botanix Agreement: Manufacturing and supply agreement for Sofdra, highlighting integrated North American network and dual-site flexibility.
• Commercial Transformation: Expanded BD team, improved go-to-market, and customer engagement driving higher win rates; multiple new logos added in Q1. NPS of ~60 supports referrals and references.
• Quality & Compliance: Sellersville facility received EIR from U.S. FDA; maintained zero OAI classification across global network.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

CDMO Growth Trajectory and Guidance

• Question: With a strong Q1, do you expect the typical H1/H2 ramp-up to continue, and will you upgrade guidance? (Amey Chalke, JM Financial)
• Answer: Historically H2 revenues are higher; this year started with a stronger opening order book. Guidance remains unchanged for FY2027; revisit after Q2. (Vivek Valsaraj)

CDMO Customer Expansion and NPS

• Question: Are top customers expanding spend with Piramal over time, or is growth reliant on replacing completed projects? (Sajal Kapoor, Antifragile Thinking)
• Answer: Top 20 customers are growing faster than overall business; many work across multiple sites and East-West networks. Strategy is "land and expand"—deliver on commitments, earn referrals. NPS ~60 vs. negative industry average. (Peter DeYoung)

Gross Margin Mix and CDMO Geography

• Question: How should we interpret subsidiary-level gross margin improvement? (Raj, Kotak AMC)
• Answer: Overseas gross margins run 75–85%, India 55–65%, blended ~64–65%. Quarterly margins are distorted by mix; do not extrapolate. (Vivek Valsaraj)

Tax Rate and Structuring

• Question: Why is tax adverse this quarter, and will it persist? (Vinod Jain, WF Advisors)
• Answer: Higher profit in tax-paying jurisdictions plus R&D credit disallowance (appeal filed) raised the rate. FY2027 tax will remain elevated; normalized rate of 24–25% only after overseas facilities scale up. No structural reorganisation planned. (Vivek Valsaraj)

Differentiated Offerings and Margin Levers

• Question: Will differentiated CDMO offerings drive EBITDA improvement toward FY2030 targets? (Bharat Sheth, Quest Investment Advisors)
• Answer: Differentiated portfolio mix is growing faster than overall business. But the single largest margin driver is operating leverage from improved overseas utilization; differentiated mix is a supporting lever. (Peter DeYoung)

ADC Pipeline and Revenue Potential

• Question: What is the revenue potential from the new Riverview payload-linker capacity? (Tushar Manudhane, Motilal Oswal)
• Answer: Single to low double-digit revenue potential; capacity already generating customer interest. Investment was <$5 million to kit out a room in the larger facility. (Peter DeYoung)

CHG ex-U.S. Growth and Chinese Competition

• Question: Does Q1 growth imply the Chinese competition issue is resolved? (Amey Chalke; Parikshit Gupta)
• Answer: Chinese competition remains, but actions taken last year are bearing fruit, particularly in ex-U.S. markets. Q1 growth rate may not be the full-year run-rate; guidance for the business is maintained. (Peter DeYoung)

Capacity Utilization and Pricing Discipline

• Question: Can you quantify utilization improvements and pricing actions? (Shyam Srinivasan, Goldman Sachs)
• Answer: No plant-level disclosures; growth is broad-based including overseas sites. Pricing discipline includes targeted price increases in CHC and measures in CDMO to offset input inflation. (Vivek Valsaraj, Peter DeYoung)

Capex and Lexington Timeline

• Question: Update on capex spend and Lexington project. (Shyam Srinivasan)
• Answer: Spent ₹21 million in Q1 against annual guidance of ₹120–135 million (as stated). Lexington on track for completion by end-2027 (calendar year). (Vivek Valsaraj)

Large Contract Destocking

• Question: Any update on the large innovator contract with prior destocking? (Alankar Garude, Kotak Institutional Equities)
• Answer: No sales anticipated in FY2027. Continuous dialogue; will communicate if situation changes materially. (Peter DeYoung)

Key Takeaway

Piramal Pharma delivered a strong start to FY2027, with revenue up 17% YoY to ₹2,270 crore and EBITDA up 72% to ₹285 crore (12.5% margin, +400 bps YoY) on broad-based mid-to-high teen growth across CDMO (+19%), Complex Hospital Generics (+17% to ₹743 crore), and Consumer Healthcare (mid-teens). Management attributes the outperformance to operating leverage, higher overseas utilization, pricing discipline, and commercial transformation—evidenced by a ~60 NPS and growing RFP flow, particularly toward overseas sites with higher margin headroom. Strategically, the company is deepening its integrated ADC franchise through the newly inaugurated Riverview payload-linker facility, Lexington sterile injectables expansion (on track for end-2027), the Ajinomoto collaboration, and the Botanix supply agreement. Guidance for FY2027 remains unchanged, with Kenalog supplies starting in Q2 and no revision despite the strong Q1. Key watchpoints include the persistence of Chinese competition in hospital generics, elevated FY2027 tax rates (normalizing to 24–25% at scale), extended CDMO customer decision timelines, and the absence of sales from the destocked large contract this fiscal year; the road to 25% EBITDA margins by FY2030 runs through overseas utilization ramp and differentiated product mix.